Novartis Consumer Health – FDA 483, Jan 20, 2012

During an FDA inspection from December 14, 2011, to January 20, 2012, Novartis Consumer Health in Lincoln, NE, was cited for significant violations of Current Good Manufacturing Practice (CGMP) regulations. The observations, many of which were repeats from prior inspections, indicate systemic deficiencies across several critical areas.The primary concerns revolved around the Quality Control Unit's failure to adequately monitor quality systems. This included a substantial backlog of over 1,300 overdue consumer complaint investigations, untimely regulatory reporting (NDA Field Alerts), and insufficient extension of investigations to all potentially affected product lots, impacting products like Excedrin, Bufferin, and Prevacid. Investigations also frequently lacked documented root causes or supporting evidence.Furthermore, manufacturing controls were found lacking, with foreign tablets repeatedly discovered on packaging lines after "major" cleaning efforts. Annual Product Reviews were deficient, failing to accurately reflect complaints or identify critical product weaknesses, even when these issues later led to product recalls. The FDA noted an inadequate number of trained Quality Unit personnel, contributing to these persistent compliance failures.Novartis is required to implement thorough and effective corrective and preventative actions to address these fundamental breakdowns in their quality system, ensuring robust oversight, timely issue resolution, proper documentation, and overall adherence to CGMP standards to safeguard drug product quality and patient safety.